Clinical trials
Relapsing Multiple Sclerosis clinical trials
Below are recruiting relapsing multiple sclerosis clinical trials, each written for real people, not researchers. We’re tracking 224 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Birmingham, AlabamaAges 18 years+ - NCT03401879Recruiting
Study eye blood-flow changes in multiple sclerosis
This study measures how blood flow in the eye changes in people with relapsing-remitting multiple sclerosis (RRMS) who previously had optic neuritis. The goal is to understand eye/brain blood-flow signals and how they may relate to MS.
Vienna, AustriaAges 18 years+ - NCT03783416RecruitingPhase 1
Ixazomib safety study for people with multiple sclerosis
This early-phase study tests how safe ixazomib is for people with multiple sclerosis (MS). It focuses on targeting certain immune cells in MS and checks whether the treatment can be given safely.
London, Greater LondonAges 18–65 - NCT03900221Recruiting
Pregnancy monitoring registry for multiple sclerosis in France
This study follows people who are pregnant and have multiple sclerosis (or related conditions) to better understand what happens during pregnancy. It does not appear to test a new treatment; it mainly collects health and pregnancy information.
AmiensAges Any age - NCT03910738RecruitingPhase 2
Testosterone treatment for nerve protection and myelin repair in MS
This Phase 2 study tests whether taking testosterone (for low testosterone levels) can help protect nerves and repair myelin in people with relapsing-remitting multiple sclerosis (MS). It may be most relevant if your MS is stable and you have low blood testosterone without current androgen treatment.
BesançonAges 18–55 - NCT03981003Recruiting
Blood tests to track brain and nerve changes in MS
This study measures blood markers (from a serum blood sample) to see how nerve and brain changes relate to MS disease activity and disability over time. It may help researchers better monitor MS, especially in people followed in the OFSEP program.
AmiensAges 15 years+ - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT04121468RecruitingPhase 1/Phase 2
Metformin trial for vision nerve recovery in young people with MS
This study tests whether metformin can help “reset” damaged nerve cells in the brain and improve vision-related nerve problems in children and young adults with multiple sclerosis. Participants are assigned to metformin or a comparison treatment in a blinded (not everyone knows which) study.
Toronto, OntarioAges 10–25 - NCT04458688Recruiting
Ocrelizumab study for relapsing MS in African Americans and Caucasians
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Detroit, MichiganAges 18–60 - NCT04480853RecruitingPhase 4
Fingolimod start study for adults with relapsing MS
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Kaohsiung CityAges 20–100 - NCT04604041Recruiting
Study early warning signs in relapsing-remitting multiple sclerosis
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
SplitAges 18–65 - NCT04806568Recruiting
Cognitive training to help brain flexibility in multiple sclerosis
This study tests whether structured cognitive exercises can improve “neuroplasticity,” meaning how flexible and changeable the brain is. It includes people with multiple sclerosis and healthy volunteers, and uses tasks plus brain scans to see what changes over time.
Thessaloniki, Central MacedoniaAges 18–65 - NCT05051618Recruiting
Exercise program for depression in people with multiple sclerosis
This trial studies whether a structured exercise program can help reduce symptoms of major depressive disorder in people who also have multiple sclerosis. You’ll complete questionnaires, wear an activity sensor, and do exercise testing while being assigned to the study program.
Chicago, IllinoisAges 18–64 - NCT05061953Recruiting
Eye-tracking test software study in adults with multiple sclerosis
This study checks how well new eye-tracking software can measure eye movements in people with multiple sclerosis. It may help researchers track changes in how the nervous system works using a simple camera-based eye test.
Montreal, QuebecAges 18 years+ - NCT05177523Recruiting
MRI study of nerve damage and repair in multiple sclerosis
This trial uses MRI scans to better understand how nerve fibers are damaged and repaired in people with multiple sclerosis. It may help researchers connect scan findings to disease activity and progression.
BaselAges 18–80 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05532943RecruitingPhase 1/Phase 2
Cord stem cell treatment for people with multiple sclerosis
This Phase 1/2 trial studies whether donated umbilical cord stem cells are safe and can improve multiple sclerosis. It aims to see if the treatment is workable for people who still have active MS despite standard therapies.
Taichung, Non-USAges 20–65 - NCT05713890Recruiting
Home VR training for right arm function in MS
This study tests whether doing a virtual-reality–based training program at home can improve movement and daily use of the right arm and hand in people with multiple sclerosis. It may help reduce hand limitations by practicing targeted movement skills using an easy remote setup.
Milan, MilanAges 18–65 - NCT05740722RecruitingPhase 2
Nicotinamide riboside for progressive multiple sclerosis
This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.
BergenAges 18–65 - NCT05748015Recruiting
Checking how the nervous system is affected in multiple sclerosis
This study looks at signs of how your automatic “control” nerves (the autonomic nervous system) may be affected in people with multiple sclerosis. It may help researchers better understand different types of MS and how to recognize nervous-system involvement.
Telese Terme, BeneventoAges 18 years+ - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55 - NCT05832515RecruitingPhase 1
Stem cell transplant for multiple sclerosis with MS-prep chemotherapy
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
Saint PetersburgAges 18–65 - NCT05834855RecruitingPhase 3
Rituximab versus ocrelizumab for relapsing multiple sclerosis
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
AmsterdamAges 18 years+ - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsing multiple sclerosis?
- Yes. Clin2 currently lists 224 recruiting relapsing multiple sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsing multiple sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsing multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Fatigue in Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.